13 completed, 5 unknown, 1 terminated, 1 withdrawn. 14 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 10, Unknown 2, Terminated 1, Withdrawn 1 |
| Phase 3 | 4 | Unknown 3, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
Follow rubitecan: new trials by email Literature Review of rubitecan trials Research Report on rubitecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aerosol L9-NC and Temozolomide in Ewing's Sarcoma Temozolomide, L9-NC - Ewing's Sarcoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 10 | 2006-06-01 | 2012-08-02 |
| Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer Rubitecan - Pancreatic Cancer | Phase 2 / Phase 3 | Terminated | Astex Pharmaceuticals, Inc. | 39 | 2005-02-01 | 2024-08-02 |
| Aerosolized Liposomal Camptothecin in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung 9-NC in aerosol reservoir - Corpus Uteri, Lung Cancer | Completed | University of New Mexico | 24 | 2003-08-01 | 2010-01-07 | |
| Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) 9-NC in aerosol reservoir - Corpus Uteri, Endometrial Cancer | Phase 2 | Completed | University of New Mexico | 39 | 2003-04-01 | 2010-01-07 |
| Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction Rubitecan - Tumors | Phase 1 | Completed | Astex Pharmaceuticals, Inc. | 54 | 2001-08-01 | 2024-08-02 |
| Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide Oral Etoposide, Oral 9-Nitrocamptothecin - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 44 | 2000-06-01 | 2012-09-26 |
| Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer rubitecan - Ovarian Cancer | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 51 | 2000-05-01 | 2012-09-24 |
| Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract rubitecan - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 21 | 2000-05-01 | 2012-09-24 |
| Nitrocamptothecin in Treating Patients With Advanced Small Cell Lung Cancer rubitecan - Lung Cancer | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 38 | 2000-05-01 | 2012-09-24 |
| Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery rubitecan - Esophageal Cancer, Gastric Cancer | Phase 2 | Unknown | Astex Pharmaceuticals, Inc. | 2000-04-01 | 2013-12-04 | |
| Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme rubitecan - Brain and Central Nervous System Tumors | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 17 | 2000-03-01 | 2012-09-24 |
| Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer rubitecan - Breast Cancer | Phase 2 | Completed | Astex Pharmaceuticals, Inc. | 1999-09-01 | 2013-12-04 | |
| Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer rubitecan - Colorectal Cancer | Phase 2 | Unknown | Astex Pharmaceuticals, Inc. | 1999-09-01 | 2013-12-04 | |
| Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas rubitecan - Gastrointestinal Stromal Tumor, Sarcoma | Phase 2 | Completed | Astex Pharmaceuticals, Inc. | 1999-06-01 | 2013-12-04 | |
| Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer rubitecan - Lung Cancer | Phase 2 | Completed | Astex Pharmaceuticals, Inc. | 1999-05-01 | 2013-12-04 | |
| Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas fluorouracil, gemcitabine hydrochloride, mitomycin C - Pancreatic Cancer | Phase 3 | Unknown | Astex Pharmaceuticals, Inc. | 1999-03-01 | 2013-12-04 | |
| Nitrocamptothecin in Treating Patients With Metastatic Melanoma rubitecan - Melanoma (Skin) | Phase 2 | Completed | Astex Pharmaceuticals, Inc. | 1999-01-01 | 2013-12-04 | |
| Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer fluorouracil, rubitecan - Pancreatic Cancer | Phase 3 | Unknown | Astex Pharmaceuticals, Inc. | 1998-11-01 | 2013-12-04 | |
| Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer gemcitabine hydrochloride, rubitecan - Pancreatic Cancer | Phase 3 | Unknown | Astex Pharmaceuticals, Inc. | 1998-11-01 | 2013-12-04 | |
| Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer rubitecan - Ovarian Cancer, Primary Peritoneal Cavity Cancer | Phase 2 | Withdrawn | Gynecologic Oncology Group | 2013-07-09 |
Pancreatic Neoplasms (4) · Lung Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Ovarian Epithelial (2) · Endometrial Neoplasms (2) · Ovarian Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Breast Neoplasms (1) · Central Nervous System Neoplasms (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Gastrointestinal Stromal Tumors (1) · Glioblastoma (1)
Astex Pharmaceuticals, Inc. (11) · European Organisation for Research and Treatment of Cancer - EORTC (4) · University of New Mexico (2) · Gynecologic Oncology Group (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1)
United States (15) · France (4) · Belgium (3) · Italy (3) · Spain (3) · Switzerland (3) · Israel (2) · Netherlands (2) · United Kingdom (1)
Show-Li Sun, MD (6) · Lawrence A. Romel, MS (3) · Pierre Fumoleau, MD, PhD (3) · Claire Verschraegen, MD (2) · Cynthia E. Herzog, MD (1) · Daniel M. Sullivan, M.D. (1) · Edward C. Grendys, MD (1) · Eric Raymond, MD, PhD (1)